Therapies targeting T cell‐suppressive cues originating from neutrophils in CRC via CXCR2, TGFBR, or MMP9 inhibitors are attractive options, and the respective compounds are currently under clinical investigation either for CRC (NCT03473925, NCT03470350) or other gastro‐intestinal cancer indications (Shah et al, 2018). Here, MMP9 is linked to colorectal carcinoma.